Table 1 Relapse-free survival and overall survival after blinatumomab retreatment

From: Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

Pt

Age a

Study

Initial treatment

Intervening alloHSCT

Retreatment

Subsequent systemic therapy

RFS (months)

Overall survival (months)

   

Daily dose

Response duration (months)

Blasts at relapse

 

Daily dose

Grade ⩾3 neurologic event

Best hematologic response

   

1

12

205

15–30 μg/m2

12.4

—

 

5–15 μg/m2

 

PD

  

0.7b

2

4

 

5–15 μg/m2

3.4

93%

Yes

5–15 μg/m2

 

No response

Yes

 

6.7

3

77

206

15 μg/m2

7.8

10%

 

15 μg/m2

Yes

PR

  

12.9

4c

38

 

5–15–30 μg/m2

17.5

10%

 

5–15–30 μg/m2

 

CR

 

8.6

 
     

32%

 

5–15–30 μg/m2

 

CR

Yes

9.7

20.0b

5

24

 

5–15 μg/m2

7.6

—

Yes

5–15 μg/m2

 

Hypocellular

  

9.4

6

62

 

15 μg/m2

d

—

Yes

15 μg/m2

 

CRh

 

3.9

4.8

7

21

 

5–15 μg/m2

10.6

10%

 

5–15 μg/m2

Yes

—

  

12.3

8

20

211

9–28 μg

14.2

—

 

9–28 μg

Yes

CR

Yes

1.7

3.7b

9

29

 

9–28 μg

10.5

—

Yes

9–28 μg

 

PD

  

0.7

10

26

 

9–28 μg

5.1

—

Yes

9–28 μg

 

PD

  

1.8

11

25

 

9–28 μg

11.3

—

Yes

9–28 μg

 

CRh

 

3.7

4.6b

          

Median (95% CI)

3.8 (1.7, 8.6)

9.4 (0.7, 12.9)

  1. Abbreviations: —, not assessed; alloHSCT, allogeneic hematopoietic stem cell transplantation; CI, confidence interval; CR, complete remission; CRh, CR with partial hematologic recovery; PD, progressive disease; PR, partial remission; RFS, relapse-free survival.
  2. aAge, in years, before initial treatment.
  3. bCensored observation (ongoing survival).
  4. cThis patient received blinatumomab retreatment twice.
  5. dDuration of response was not calculated for this patient because the initial response occurred after blinatumomab treatment ended.
Back to article page